Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsBNGOW 60 Receivables Turnover is 1.43 as of Mar. 2026. GuruFocus rates BNGOW with a GF Score™ of 60/100. The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Bionano Genomics ranks better than 67.45% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bionano Genomics's Revenue for the
three
months ended in Mar. 2026 was $6.69 Mil. Bionano Genomics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4.67 Mil.
Hence, Bionano Genomics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bionano Genomics Receivables Turnover Related Terms
Bionano Genomics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNGOW vs RGNT, UEEC, FEMY: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (BNGOW) has a Receivables Turnover of 1.43 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #264 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 32.6%.
Is Bionano Genomics' Receivables Turnover too high?
Bionano Genomics' current Receivables Turnover is 1.43. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Bionano Genomics' value of 1.43 is 74% below this industry median. Based on the distribution chart, Bionano Genomics ranks #264 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Receivables Turnover compare to RGNT and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #264 out of 811 companies for Receivables Turnover. This puts Bionano Genomics in the upper half of its industry. The industry median Receivables Turnover is 5.51. Bionano Genomics' value of 1.43 is 74% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current Receivables Turnover of 1.43 is 74% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Receivables Turnover is 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Receivables Turnover of 1.43. The current Receivables Turnover is 1.43 and 74% below the Medical Devices & Instruments industry median of 5.51. Bionano Genomics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Receivables Turnover is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
60GF Score
Get the complete analysis for BNGOW
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
